The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 24, 2021

Filed:

Jul. 01, 2017
Applicants:

Chinook Therapeutics, Inc., Seattle, WA (US);

Novartis Ag, Basel, CH;

Inventors:

David Braun Kanne, Court Madera, CA (US);

Chudi Obioma Ndubaku, Oakland, CA (US);

Jacob Robert Bruml, San Francisco, CA (US);

Thanh Ngoc Lan Le, Berkeley, CA (US);

Jeffrey McKenna, Cambridge, MA (US);

George Scott Tria, Cambridge, MA (US);

Stephen Canham, Cambridge, MA (US);

Assignees:

CHINOOK THERAPEUTICS, INC., Seattle, WA (US);

NOVARTIS AG, Basel, CH;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 17/06 (2006.01); A61P 31/00 (2006.01); A61P 37/06 (2006.01); A61P 3/10 (2006.01); A61P 1/00 (2006.01); A61K 9/00 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C07H 21/00 (2013.01); A61K 9/0019 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 3/10 (2018.01); A61P 17/06 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C12N 15/113 (2013.01);
Abstract

The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2', 4′ locked nucleic acids within the cyclic dinucleotide.


Find Patent Forward Citations

Loading…